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ABSTRACT 
A novel drug delivery system is the one that ensures optimum dose at the right time, at the right location. Porphysomes are among those drug 
delivery systems. Porphysomes are a means of vesicular drug delivery systems. They are liposome-like structures composed completely of 
porphyrin lipid. The porphysomes encapsulates the active medicament in vesicular structure. They are having an aqueous core which can be loaded 
with the medicament. They have the capacity to destroy the disease tissues. They absorb the heat in the near infrared region and release this heat to 
destroy the diseased tissues. Porphysomes are having immense applications in the field of positron-electron therapy (PET), photoacoustic imaging, 
photothermal therapy etc. This review article discusses regarding the Porphysome-the drug delivery system, its advantages and disadvantages, 
composition, method of preparation, applications and various aspects related to the porphysomal drug delivery. 
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In the past few years, a great focus has been laid on the development of 
different novel drug delivery systems (NDDS) [1-5]. A novel drug 
delivery system is the one that ensures optimum dose at the right time 
and at the right location. It brings together approaches, formulations, 
technologies for transporting a drug in the body in order to exhibit its 
desired therapeutic effects [6-10]. For the last few years, many NDDS has 
come in to use such as liposomes, sphingosomes, niosomes etc. But now 
the NDDS is towards a new discovery, the porphysomes. 
The porphysomes are a means of vesicular drug delivery systems. 
They encapsulate the active medicament in a vesicular structure 
[11]. They are liposome-like structures composed completely of 
porphyrin lipid. Porphysomes are bilayered spherical nano-sized 
vesicles formed from the self-assembled porphyrins. Each porphyrin 
is having a diameter of 100 nm. Like liposomes, porphysomes are 
having an aqueous core that can be loaded with therapeutic drugs 
[12]. These vesicular systems enhance the existence of drugs in 
systemic circulation and thereby decreases toxicity. It possesses 
multimodal biophotonic properties. They are used in photoacoustic 
imaging, positron emission tomography (PET), magnetic resonance 
imaging (MRI) and image tracked drug delivery. Porphysomes are 
phototherapy agents. They have the capacity to destroy the diseased 
tissues. They absorb the light in the near-infrared region and then 
releases this heat to destroy the diseased tissues. 
Many forms of inorganic compounds were used for thermal 
phototherapy and photoacoustic imaging because these compounds 
are having high biophotonic properties. But these inorganic 
compounds are non-biodegradable and also have long-term toxicity. 
All these challenges were overcome by the introduction of novel 
colloidal drug delivery system called porphysomes. They possess 
strong biophotonic properties and are completely composed of 
organic porphyrin-lipid units. 
Novel drug delivery systems 
A novel drug delivery system is a system that helps in maintaining 
the concentration of drug in therapeutically effective range. Some 
drugs exhibit their maximum effect within an optimum 
concentration range. Either no therapeutic activity is produced by 
the drug below this optimum concentration or toxicity is produced 
above this concentration [13].  
Controlled drug delivery systems 
Controlled drug delivery system is a mode of drug delivery that 
ensures uniform concentration of drug to the site of absorption. Due 
to this property, it maintains plasma concentration within the 
therapeutic range, as in fig. 1 [14]. It helps to reduce the frequency of 
administration. It also minimizes the toxicity caused by drugs. 
 
 
Fig. 1: Controlled drug delivery system for drug delivery 
 
Carriers used in targeted drug delivery 
Carriers which are also called as vehicles or drug vectors are the most 
important component of a targeted drug delivery system that helps in 
the successful transportation of the drug to the specified sites.  
Characteristics of an ideal carrier 
• It should be able to cross the blood-brain barrier (BBB) 
• It should maintain the specificity of the surface ligands  
• It should be specifically recognized by the target cells 
• A stable drug-ligand complex must be formed 
• The carriers used should be biodegradable, non-toxic and non-
immunogenic in nature 
• The carrier systems after recognizing the target sites should release 
the drugs inside the specific organs, tissues or cells [15]. 
Porphysomes as a lipoidal drug carrier  
Among lipoidal biocarriers ‘Porphysomes’ are the emerging drug 
delivery systems under study. As discussed earlier, they are 
liposome-like structures composed completely of porphyrin lipid. 
They possess a lipoidal bilayered structure, encapsulating the active 
ingredient in the central core. Porphysomes comprise of a 
phospholipid bilayer and possess a porphyrin ring [16].  
Composition of porphysomes 
Porphysomes are composed of porphyrin and phospholipid. 
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Porphyrins are the building blocks of porphysomes. They are 
heterocyclic organic compounds which are made up of four pyrrole 
subunits which are interconnected by methane bridges at their α 
carbon as depicted in fig. 2 [17]. The porphyrin is having 26 
electrons in its conjugated system. 
They mostly occur naturally in pigments like haemoglobin (heme), 
chlorophyll in plants etc. 
 
 
Fig. 2: Porphyrin 
 
Phospholipids 
Phospholipids are major components of cell membranes. They are 
mainly composed of two hydrophobic fatty acid tails and hydrophilic 
heads consisting of phosphate group as shown in fig. 3 [18]. They are 
amphiphilic in nature, hence can form bilayers [19, 20]. 
 
 
Fig. 3: Phospholipid bilayer 
 
There are different types of phospholipids used based on the 
changes in the aliphatic chain, head groups and alcoholic parts. Some 
of those examples are;  
 Phosphotidyl Choline (Lecithin) 
 Phosphotidyl Ethanolamine (Cephalin) 
 Phosphotidyl Serine  
 Phosphotidyl Inositol [21, 22]. 
Advantages and disadvantages of porphysomes [23-26] 
The porphysomes have a large number of advantages when 
compared with other forms of drug delivery systems. Along with 
advantages, these are also having disadvantages too. The advantages 
and disadvantages are given in table 1. 
Table 1: Advantages and disadvantages of porphysomes 
Advantages of porphysomes  Disadvantages of porphysomes 
1) Increases bioavailability of drugs 
2) Decreases toxicity effect of certain drugs  
3) Increases the stability of drugs via encapsulation 
4) Reduce exposure of sensitive tissues to toxic drugs 
5) Increases circulation lifetime of drugs 
6) Delays the elimination of rapidly metabolisable drugs  
7) Completely biodegradable 
8) Easily modifiable 
1) Encapsulated drugs are viable to leakage 
2) Less stability 
3) Short half-life 




Porphysome nanovescicles are formed by the self-assembly of 
‘porpholipids’. By chemically fusing porphyrin molecules with 
phospholipids, porpholipids are created. These porpholipids 
spontaneously assembles into bilayers, or lipid sheets, when these 
are suspended in water and heated.  
Then these bilayers can be forced out through a tiny perforated 
membrane to form balloon-like nanoparaticle with a diameter of 
100 nm, which are termed as porphysomes, as depicted fig. 4 [27]. 
 
 
Fig. 4: Preparation of porphysomes 
Properties of porphysomes 
The porphysomes possess a large number of properties. Some of the 
properties are given below:  
1) Photothermal therapy 
2) Photodynamic therapy 
3) Photoacoustic imaging 
4) Exploitation of stable Cu2+ 
5) Radiolabelling 
6) Liposomal properties 
1) Photothermal therapy  
Photothermal therapy is one of the latest developed therapeutic 
strategy, that uses the near-infrared (NIR) laser photoabsorbers,which 
upon NIR laser irradiation generate heat and thermally ablate the 
cancer cells. Phototherml therapy are very advantageous in cancer 
therapy. They exhibit high specificity, minimal invasiveness, precise 
temporal selectivity. They directly eradicate cancer cells in the 
primary tumor. The complete information regarding the photothermal 
therapy is explained in Jilon Wang et al. [28, 29]. 
2) Photodynamic therapy 
Photodynamic therapy is a type of treatment which uses 
photosensitisers for the destruction of cancerous cells. It is a 
minimal invasive mode of treatment. Photosensitisers have an 
ability to produce a biochemical reaction by absorbing the light [30]. 
The photosensitizers used initiates a cytotoxic activity towards 
malignant cancerous cells. The cytotoxic activity is due to the 
generation of ‘singlet oxygen’.  
Nair et al. 
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The photosensitisers used in photodynamic therapy are mostly 
tetrapyrrole derivatives, like protoporphyrins [31]. 
A schematic diagram depicted in Januz B et al., explain the different 




Fig. 5: Photodynamic therapy 
 
3) Photoacoustic imaging 
The photoacoustic imaging refers to the generation of acoustic 
waves, by absorbing the electromagnetic energy [33]. The radio 
frequency (rf) pulses or short pulses, which are non-ionising waves, 
are used to excite the megahertz ultrasound waves, referred to as 
photoacoustic or thermoacoustic signals, in biological tissues. Non-
ionizing waves are used upon ionising waves because the former 
does not cause any health hazards. The general steps involved in the 
process of photoacoustic imaging is depicted below in fig. 6 [34]. 
 
 
Fig. 6: Steps in photoacoustic imaging 
 
4) Radiolabelling 
Radiolabeling is a technique used for tracking the passage of a 
sample substance through a biological system. Radionucleotides are 
used to label the substance, in its chemical composition. These 
radionucleotides gets decayed, and emit minute amounts of 
radioactivity. This helps in tracking their presence in the body. 
Radiolabeling is having a critical importance in drug development 
process [35]. 
5) Liposomal properties 
Liposomes are one of the vesicular, targeted drug delivery systems. 
These are spherical vesicles consisting of one or more phospholipid 
bilayers [36]. These systems are having both hydrophobic and 
hydrophilic characters. Their size ranges from 30 nm to several 
nanometers[37,38]. They are highly biocompatible, non-toxic, 
biodegradable. Due to all these properties, liposomes are used as 
carriers of both hydrophilic andn lipophilic drugs.  
Porphysomes possess all these properties as that of liposomes. 
Porphysomes are also vesicular, made of a phospholipid bilayer, 
biodegradable etc. As dicussed earlier porphysomes are having large 
aqueous core which can be loaded with drugs. This is also another 
property that resembles liposomes.  
Compounds with porphyrin ring 
1) Hemoglobin 
Hemoglobin is a protein molecule that is present in the red blood 
cells [RBC] which is made up of two parts: heme and globin. It is 
made up of four protein molecules that are connected together. 
Heme part of hemoglobin is a porphyrin compound which carries an 
iron group as shown in fig. 7 [39]. The centre of porphyrin ring is 
occupied by the iron. This iron is linked to all the four nitrogen 
atoms of all pyrrole rings of porphyrin. It is also linked to the 
nitrogen of imidazole ring present in the globin part i. e to the 
histidine. Four polypeptide chains, two α and two β chains, 
constitute the globin part. α2 β2 forms the normal adult hemoglobin. 




Fig. 7: Structure of hemoglobin 
 
2) Chlorophyll 
Chlorophyll is a green colour pigment seen in the leaves and stems 
of green plants. It is a chemical compound that helps the plants to 
make energy by capturing the sunlight. It gives plants the green 
colour [41]. The basic structure of chlorophyll is the porphyrin ring 
with a central atom, a metal atom. Here the central metal atom is 
magnesium. The central metal atom is bonded to the nitrogen atoms 
of the four pyrrole rings of the porphyrin ring. 
Nair et al. 
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The chlorophyll is a chemoprotective agent. It has an abiliy to 
prevent the absorption of toxins. It also possesses anti-microbial 
properties [42]. 
3) Myoglobin 
Myoglobin is another pigment/molecule that carries a porphyrin 
ring. It is having a similar structure as that of hemoglobin. It gets its 
name as it possess same structure as well as functions as 
hemoglobin. It is a hemoprotein present in cytoplasm. Like 
hemoglobin, myoglobin binds with O2 and also plays a major role in 
the transport of oxygen from RBC to mitochondria. It is a oxygen 
storage protein in the muscles [43]. It is primarily seen in 
cardiomyocytes and oxidative skeletal muscles. It helps in the nitric 
oxide homeostasis in skeletal muscles [44-46]. 
4) Cobalamine 
Cobalamine is also called as ‘vitamin B12’. It is a compound consisting 
of a tetrapyrrole ring with cobalt as the central metal atom. Such a 
structure is called as corrin ring. It is a similar structure as that of 
the porphyrin ring. A small difference is that the corrin ring lacks a 
carbon when compared to porphyrin as shown fig. 8 [47]. 
 
 
Fig. 8: Corrin ring 
 
5) Phycobilin 
Phycobillins are group of compounds that act as a chromophore in 
the light harvesting chromoproteins. It is having an open chain tetra-
pyrrole structure. These phycobillins are efficient absorbers of 
colours like red, blue, orange etc. There are different types of 
phycobillins:  
a) Phycoerythrobilin-produces red 
b) Phycourobilin-produces orange 
c) Phycoviolobilin 
d) Phycocyanobilin-produces blue [48] 
Applications of porphysome nanovesicles 
Porphysomes have a wide range of clinical applications. Some of 
these are illustrated. 
1) Pancreatic cancer therapy 
Pancreatic cancer is one a kind of cancer where the local disease 
control is of greater concern. It is a disease in which cancerous cells 
develop in the tissues of pancreas. The pancreas is a gland located 
behind the stomach and in front of the spine. Pancreatic tumor is 
often undiagnosed until there is an appearance of clinical symptoms 
and signs of advanced disease [49]. The primary tumor of pancreatic 
cancer cannot be surgically resectioned in all the patients. 
Photothermal therapy can be used for the focal ablation of 
pancreatic tumor. Photothermal sensitizers in helps in the efficient 
conversion of light energy to heat and the thermal destruction of the 
tumor cells with improved special confinement. By fluorescence 
intensity measurements the accumulation and distribution of tumor 
can be evaluated. These studies give information regarding the 
influence of heat on thermal therapy for pancreatic tumors [50]. 
2) Selective destruction of prostate tumor using MRI guided 
photothermal therapy 
The prostate is a gland that produces a white fluid. It is located 
below the urinary bladder and near the base of penis. Almost all 
pancreatic cancers are called adenocarcinomas. They are cancers 
that start in cells that lines the glands. Most pancreatic cancers start 
at in the prostate-specific antigen. The prostate-specific antigen, is a 
protein that is seen inside the prostate gland, and is made by fluid 
making cells in the gland [51]. Prostate tumors can be almost 
destructed by using MRI guided photothermal therapy. 
The magnetic resonance imaging-guided laser therapy showed a 
response in phase 1 trial of low/intermediate-risk localized prostate 
cancer. This treatment lacked the tumor selectivity as well as had low 
efficiency of thermal heat generation. In order to resolve this 
drawback, porphysome nanoparticles have been used to treat 
localized prostate cancer, having high efficiency and tumor selectivity. 
Porphysome enabled photothermal eradication of tumor cells without 
damaging adjacent organs and tissues [52-54]. Porphyrin molecules 
are fluorescent, naturally. By using a light at one wavelength (~410 
nm), these molecules are excited. This excitation leads to the re-
emission of light of higher wavelength (~600 nm). A charge-coupled 
device can be used to detect this emitted light. The porphysomes 
accumulate in the prostate tumors and create an optical signal. This 
signal is used by surgeons to see the tumor margins during surgery. By 
making these margins visible, it possible to either removes or ablate 
tumors by sparing the normal surrounding tissues.  
3) Treatment of central serous retinopathy 
Central serous retinopathy (CSR), is an ophthalmic disease which 
leads to vision loss. It is also called as central serous 
chorioretinopathy (CSCR) and central serous choroidopathy. It 
usually affects one of the eye. This disease is often characterized by 
fluid leakage under the retina. It results from the buildup of fluid 
under retina. This leads to visual impairment. It is also characterized 
by a serous detachment of neurosensory retina [55, 56]. 
This disorder can be effectively cured with the intake of a drug 
named Verteporfin. Verteporfin is a benzoporphyrin derivative. It is 
used for photodymanic therapy (PDT) as a photosensitizer. It 
eliminates the abnormal blood vessels in the eye. Verteporfin 
accumulates in these blood vessels and gets stimulated by 
nonthermal red light in the presence of oxygen, leads to the 
formation of reactive oxygen radicals, resulting in the local 
endothelial damage and blockage of blood vessels [57]. 
4) Flourescence guided transbronchial photothermal therapy 
Flourescence guided transbronchial photothermal therapy for the 
treatment of peripheral lung cancer was discovered enabling the 
porphysomes fig. 9 [58]. The efficiency of transbronchial 
photothermal therapy was enhanced with the incorporation of 
porphysomes. Porphysomes enabled the selective and efficient 
ablation of the tumor in the rabbit model. Lung cancer is divided into 
small cell lung cancers and non-small cell lung cancers [59, 60]. 
 
 
Fig. 9: Detection of cancer cells by porphysomes through 
fluorescence therapy 
 
5) Ovarian cancer treatment with porphysomes 
Ovarian cancer is the sixth most common cancer among women. It is 
one of the most dangerous gynaecologic malignancy in many 
countries including India [61]. Ovarian cancer is defined as the 
growth of cancerous cells in the ovary. The porphysomes are largely 
used for the treatment of ovarian cancers in the recent era. 
Nair et al. 




Vesicular drug delivery system plays an important role in selective 
targeting of various types of drugs. Among them, Porphysomes are 
an emerging as well as a more preferred drug delivery system. It can 
be used as an alternative drug delivery system for liposomes as it 
presents a similar structure as that of liposomes. It also possess a lot 
of advantages over liposomes and other systems. A review on 
liposomes by Nair et al., explains the properties of liposomal drug 
delivery sytems. From this review, almost all the characters of these 
carriers are well understood and that helps to compare these 
characters with the porphysomal drug delivery sytems. 
Porphysomal drug delivery systems are having a wide range of 
applications in the field of photothermal therapy, photoacoustic 
imaging, radiolabeling etc. It is having very high bioavailability as 
compared to other forms of drug delivery systems.  
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